Citation: | NIU Wen-shu, LIU Yang, WANG Yu-bin, NING Qun, LI Zhi-yun. Observation on efficacy of tirofiban in patients with ischemic progressive stroke[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2019, 23(4): 489-492. doi: 10.16462/j.cnki.zhjbkz.2019.04.024 |
[1] |
张宇, 汤颍, 王红, 等. 大动脉粥样硬化型急性缺血性脑卒中患者入院后首个24小时内血压变异与出院结局[J]. 中华疾病控制杂志, 2018, 22(8): 776-780. DOI: 10.16462/j.cnki.zhjbkz.2018.08.004.
Zhang Y, Tang Y, Wang H, et al. Blood pressure variability within the first 24 hours after admission and discharge outcome in acute ischemic stroke patients with large-arteryatherosclerosis[J]. Chin J Dis Control Prev, 2018, 22(8): 776-780. DOI: 10.16462/j.cnki.zhjbkz.2018.08.004.
|
[2] |
李娟, 黄东辉, 王冲, 等. 辽宁省农村地区2013年脑卒中早死所致的疾病负担分析[J]. 中华疾病控制杂志, 2017, 21(3): 255-260. DOI: 10.16462/j.cnki.zhjbkz.2017.03.010.
Li J, Huang DH, Wang C, et al. Analysis of the disease burden of stroke-related deaths among rural areas of Liaoning Province in 2013[J]. Chin J Dis Control Prev, 2017, 21(3): 255-260. DOI: 10.16462/j.cnki.zhjbkz.2017.03.010.
|
[3] |
徐淑华, 孙静, 钱金明, 等. 脑卒中高危人群知信行调查及其影响因素分析[J]. 中华疾病控制杂志, 2017, 21(8): 857-859. DOI:10.16462/j.cnki.zhjbkz.2017. 08.025.
Xu SH, Sun J, Qian JM, et al. Investigation and analysis of KAP among high risk population of stroke[J]. Chin J Dis Control Prev, 2017, 21(8): 857-859. DOI:10.16462/j.cnki.zhjbkz.2017. 08.025.
|
[4] |
Del BA, Palumbo V, Lamassa M, et al. Progressive lacunar stroke: Review of mechanisms, prognostic features, and putative treatments[J]. Int J Stroke, 2012, 7(4): 321-329. DOI: 10.1111/j.1747-4949.2012.00789.x
|
[5] |
Januzzi JL, Jr., Snapinn SM, DiBattiste PM, et al. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: Results from the platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (prism-plus) trial[J]. Circulation, 2002, 105(20): 2361-2366. doi: 10.1161/01.CIR.0000016359.94919.16
|
[6] |
Siebler M, Hennerici MG, Schneider D, et al. Safety of tirofiban in acute ischemic stroke: The satis trial[J]. Stroke, 2011, 42(9): 2388-2392. DOI: 10.1161/STROKEAHA.110.599662
|
[7] |
Junghans U, Seitz RJ, Aulich A, et al. Bleeding risk of tirofiban, a nonpeptide gpiib/iiia platelet receptor antagonist in progressive stroke: An open pilot study[J]. Cerebrovasc Dis, 2001, 12(4): 308-312. DOI: 10.1159/000047726
|
[8] |
Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment[J]. Stroke, 1993, 24(1): 35-41. doi: 10.1161/01.STR.24.1.35
|
[9] |
Meyer BC, Hemmen TM, Jackson CM, et al. Modified national institutes of health stroke scale for use in stroke clinical trials: Prospective reliability and validity[J]. Stroke, 2002, 33(5): 1261-1266. doi: 10.1161/01.STR.0000015625.87603.A7
|
[10] |
Torgano G, Zecca B, Monzani V, et al. Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: A double-blind randomized trial[J]. Cerebrovasc Dis, 2010, 29(3): 275-281. DOI: 10.1159/000275503.
|